Miltefosine
(Synonyms: 米替福新; HePC; Hexadecyl phosphocholine) 目录号 : GC10811
An inhibitor of CCT
Cas No.:58066-85-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
L6E9 rat skeletal muscle cell line |
|
Preparation method |
The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
10, 20, 40 or 60 μM; 15, 30, 45 or 60 mins |
|
Applications |
In L6E9 rat skeletal muscle cell line, Miltefosine dose-dependently inhibited insulin-stimulated Akt/PKB phosphorylation, with 75% inhibition at 40 μM and 98% inhibition at 60 μM. Besides, Miltefosine (40 μM for 60 mins) pre-treatment also inhibited insulin-stimulated activation of PI3K, without significant effect on cell survival, cell number, protein content or cell morphology. |
| Animal experiment [2]: | |
|
Animal models |
BC-1 cell-xenografted NOD-SCID mice |
|
Dosage form |
50 mg/kg; i.p.; 5 days a week, for 20 days |
|
Applications |
Compared with vehicle-treated mice, Miltefosine showed inhibition on the growth rate of tumors. By day 14 after treatment, there was an approximately 50% decrease in the average tumor volume of Miltefosine-treated mice. Immunohistochemical analyses of tumor sections from Miltefosine-treated mice displayed reduced phosphorylation of ribosomal S6 protein which correlated with the delay in tumor progression in the treatment group. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Verma, N.K. and C.S. Dey, The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia, 2006. 49(7): p. 1656-60. [2]. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010 Jun 3;115(22):4455-63. | |
Miltefosine is an inhibitor of PI3K/Akt signaling with IC50 value of 34.6±11.7μM, 6.8±0.9 μM when tested with MCF7 and Hela-WT respectively [1].
PI3K (phosphoinositide-3-kinase) family is an important part in the growth factor super-family signaling process, and can be activated by a variety of cytokines and chemical factors. The activation of PI3K can phosphorylate and activate AKT, localizing it in the plasma membrane. The PI3K/Akt pathway is an intracellular signaling pathway which plays an important role in regulating cell cycle, such as cellular quiescence, proliferation, cancer, longevity and so forth [2, 3]. Many studies have shown that PI3K/Akt had abnormal expression in patients with cancer or virus infection.
Miltefosine is an inhibitor for PI3K/Akt signaling. When tested with macrophages infected by human HIV-1 virus, miltefosine showed significant ability to reduce the viral production via inhibiting PI3K/Akt signaling pathway [4]. In L6E9 skeltal muscle cell line, treatment of milefosine resulted in the resistance of skeletal muscle cells via inhibiting PI3K/Akt signaling pathway [5].
References:
[1]. Rybczynska, M., et al., MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer, 2001. 84(10): p. 1405-11.
[2]. Bauer, T.M., M.R. Patel, and J.R. Infante, Targeting PI3 kinase in cancer. Pharmacol Ther, 2015. 146c: p. 53-60.
[3]. Minami, A., et al., Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Front Oncol, 2014. 4: p. 318.
[4]. Chugh, P., et al., Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology, 2008. 5(11): p. 1742-4690.
[5]. Verma, N.K. and C.S. Dey, The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia, 2006. 49(7): p. 1656-60.
| Cas No. | 58066-85-6 | SDF | |
| 别名 | 米替福新; HePC; Hexadecyl phosphocholine | ||
| 化学名 | hexadecyl 2-(trimethylazaniumyl)ethyl phosphate | ||
| Canonical SMILES | CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C | ||
| 分子式 | C21H46NO4P | 分子量 | 407.57 |
| 溶解度 | ≥ 10.2mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4536 mL | 12.2678 mL | 24.5357 mL |
| 5 mM | 0.4907 mL | 2.4536 mL | 4.9071 mL |
| 10 mM | 0.2454 mL | 1.2268 mL | 2.4536 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。